Abstract:To evaluate if breast-conserving therapy achieved superior efficacy to modified radical mastectomy in patients with T1-2N1M0 breast cancer. 2776 women with T1-2N1M0 breast cancer treated from 1999 to 2013 were retrospectively reviewed. All had received lumpectomy or mastectomy and axillary lymph node dissection without neoadjuvant chemotherapy. The median age was 49 years. 2484 patients underwent modified radical mastectomy (MRM), 580 (23.3%) of them received postoperative RT (MRM + RT). 292 patients received breast-conserving surgery (BCT), all of them received postoperative RT. For the whole group, 92.7% of received postoperative chemotherapy and 4.9% received trastuzumab targeted therapy. Of the 2148 patients with ER and/or PR positive, 87.7% received hormonal therapy. Survival and recurrence rates were calculated by using the Kaplan-Meier method and compared by log-rank test. Multivariable analysis was estimated by using the Cox proportional hazards model. At a median follow-up of 59 months (range, 1-257 months), the 5-year overall survival (OS) of the BCT and MRM groups was 97.9% and 92.9% (p= 0.014), and the 5-year locoregional recurrence (LRR) was 2.3% vs 6.1% (p= 0.022). Of MRM group, the 5-year OS was 92.7% in MRM alone and 93.5% in MRM + RT (p = 0.037), and the 5-year LRR was 6.3% and 5.2%, respectively (p = 0.188). Furthermore, the 5-year OS of BCT group was significantly higher than that of MRM alone (p = 0.007), however there was no significant difference in OS between BCT and MRM + RT (P = 0.160). The 5-year LRR of BCT group was significantly lower than that of MRM alone (p = 0.016), but had no significant difference with MRM + RT (p = 0.094). Univariate analysis showed that age ≤ 60 years, tumor grade I-II, T1, luminal subtype, no lymph-vascular invasion, BCT, RT, chemotherapy and hormonal therapy were favorable factors of OS (P <0.05). Age > 60 years, tumor grade I-II, T1, one axillary lymph node metastasis, luminal subtype, BCT, RT and hormonal therapy were favorable factors of LRR (P <0.05). Multivariate analysis showed that age (p = 0.009), T stage (p <0.001), molecular subtype (p = 0.009) and chemotherapy (p <0.001) were independent prognostic factors for OS. RT (p = 0.054) and hormonal therapy (p = 0.063) had a trend to improve OS. Age (p = 0.034), T stage (p = 0.002), molecular subtype (p <0.001), RT (P = 0.001) and the number of positive axillary lymph node (P <0.001) were independent prognostic factors for LRR. The type of breast surgery had no significant effect on OS (p = 0.388) and LRR (p = 0.836). The type of breast surgery had no significant effect on the prognosis of patients with T1-2N1M0 breast cancer. Postoperative radiotherapy significantly reduces the risk of locoregional recurrence and might improve overall survival, suggesting that it may be required for majority of patients with mastectomy.

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

The value of radiotherapy in patients with T1-2 N1 M0 triple-negative breast cancer after modified radical mastecomy

Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy.

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer.

Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy

Postmastectomy Radiation Therapy Reduces Locoregional Recurrence and Disease Recurrence in Triple-Negative Breast Cancer Patients with Stage Ii-Iii Treated with Neoadjuvant Chemotherapy and Mastectomy

T1-2N1M0 Triple-Negative Breast Cancer Patients from the SEER Database Showed Potential Benefit from Post-Mastectomy Radiotherapy.

Improved locoregional control with conventional radiotherapy following modified radical mastectomy for patients with T1-2N1M0 triple-negative breast cancer

Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.

The Effect of Postmastectomy Radiotherapy in Node-Positive Triple-Negative Breast Cancer

Post-mastectomy Radiotherapy Can Improve Survival in Breast Cancer Patients Aged 35 Years or Younger with Four or More Positive Nodes but Not in One to Three Positive Nodes

Clinical Value of Radiotherapy in 78 Patients with Pt3 N0 M0 Breast Cancer after Modified Radical Mastectomy

The Role of Postmastectomy Radiation Therapy in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Abstract P1-14-18: Postmastectomy Radiotherapy Improves the Outcomes of Stage III Breast Cancer Patients with Negative Lymph Nodes after Neoadjuvant Chemotherapy

Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?

The Role of Postmastectomy Radiotherapy in Different Molecular Subtypes of Breast Cancer Patients with T 1 - T 2 and One to Three Positive Axillary Nodes

Postmastectomy Radiation Therapy Does Not Improve Outcome for Pathologic T3N0 Breast Cancers

The Role of Postmastectomy Radiotherapy in Breast Cancer Patients with T1-T2 and One to Three Positive Axillary Nodes

Post-Mastectomy Radiotherapy For Breast Cancer Patients With T1-T2 And 1-3 Positive Lymph Nodes: A Meta-Analysis